SAG
KRYS icon

SageView Advisory Group’s Krystal Biotech KRYS Stock Holding History

SageView Advisory Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$14.1K Buy
+57
New +$12K ﹤0.01% 1588

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SageView Advisory Group's KRYS Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Krystal Biotech (KRYS) in Q4 2025: 57 shares worth $14.1K. The stake represents ﹤0.01% of the portfolio and ranks #1588 among its holdings.

334 funds tracked by Wall St. Rank hold KRYS as of Q4 2025.

  • SageView Advisory Group held 57 shares of Krystal Biotech worth $14.1K as of Q4 2025.
  • Krystal Biotech was a new SageView Advisory Group position in Q4 2025.
  • Krystal Biotech made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #1588 holding.
  • 334 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.